Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Han BiomedicalROCO:6999 26 Days Payable is 81.49 as of Dec. 2025, which is 104% above its 10-year median of 40.02. GuruFocus rates ROCO:6999 with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, Han Biomedical ranks worse than 61.68% on this metric.
The historical rank and industry rank for Han Biomedical's Days Payable or its related term are showing as below:
ROCO:6999'
s Days Payable Range Over the Past 10 Years
Min: 29.31 Med: 40.02 Max: 64.92
Current: 64.92
During the past 5 years, Han Biomedical's highest Days Payable was 64.92. The lowest was 29.31. And the median was 40.02.
ROCO:6999's Days Payable is ranked worse than 61.68% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs ROCO:6999: 64.92
Han Biomedical's Days Payable
increased
from Dec. 2024 (80.12) to Dec. 2025 (81.49).
It may suggest that Han Biomedicaldelayed paying its suppliers.
Han Biomedical Days Payable Related Terms
Han Biomedical Days Payable Historical Data
* Premium members only.
The historical data trend for Han Biomedical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6999 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Han Biomedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Han Biomedical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Han Biomedical's Days Payable distribution charts can be found below:
* The bar in red indicates where Han Biomedical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Han Biomedical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Han Biomedical (ROCO:6999) has a Days Payable of 81.49 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Han Biomedical and its competitors. This is 104% above median its historical median of 40.02. Over the past decade, Han Biomedical's Days Payable has ranged from 29.31 to 64.92. According to the industry distribution chart, Han Biomedical ranks #433 out of 702 companies in the Biotechnology industry, placing it in the top 61.7%.
Is Han Biomedical's Days Payable too high?
Han Biomedical's current Days Payable of 81.49 is 104% above median its 10-year median of 40.02. Over the past 10 years, this metric has ranged from a low of 29.31 to a high of 64.92. The Biotechnology industry median Days Payable is 113.10. Han Biomedical's value of 81.49 is 27.9% below this industry median. Based on the distribution chart, Han Biomedical ranks #433 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Han Biomedical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Han Biomedical ranks #433 out of 702 companies for Days Payable. This places Han Biomedical in the lower half of its industry. The industry median Days Payable is 113.10. Han Biomedical's value of 81.49 is 27.9% below this benchmark. Historically, Han Biomedical's own Days Payable has ranged from 29.31 to 64.92 over the past decade. While the company's 10-year median is 40.02 vs. the industry median of 113.10, Han Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Han Biomedical's current Days Payable of 81.49 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Han Biomedical and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Han Biomedical's current Days Payable is 81.49, which is 104% above median its own 10-year median of 40.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current Days Payable of 81.49. The current Days Payable is 81.49, which is 104% above median its 10-year median of 40.02 and 27.9% below the Biotechnology industry median of 113.10. Han Biomedical's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current Days Payable is 81.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6999 has been successfully added to your 
